Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Impedimed Limited ( (AU:IPD) ).
ImpediMed Limited has appointed U.S. medtech veteran Erik Anderson as an independent non-executive director, adding deep commercial experience from his tenure leading major business units at Hologic, including Breast & Skeletal Health and Cynosure. Anderson’s background in breast health, body composition and medical aesthetics closely aligns with ImpediMed’s priorities in breast cancer-related lymphoedema, heart health and body composition, strengthening the company’s U.S. commercial capabilities.
The board sees his appointment as reinforcing ImpediMed’s strategic focus on the growing cancer survivorship sector and the expansion of its SOZO digital platform across oncology and broader chronic care. With guidelines continuing to endorse bioimpedance spectroscopy for early lymphoedema detection and ImpediMed uniquely offering FDA-cleared BIS-based lymphoedema assessment, the new board addition is expected to support the company’s efforts to capitalise on a large U.S. market opportunity and drive SaaS subscription growth.
The most recent analyst rating on (AU:IPD) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is a Brisbane-headquartered medical technology company that uses bioimpedance spectroscopy to generate clinical data aimed at maximising patient health. Its flagship product is the SOZO Digital Health Platform, which is FDA-cleared, CE-marked and ARTG-listed for indications including lymphoedema, heart failure and protein calorie malnutrition, and is sold globally through a SaaS-driven model focused on cancer-related lymphoedema screening and management.
Average Trading Volume: 5,364,483
Technical Sentiment Signal: Sell
Current Market Cap: A$36.7M
For detailed information about IPD stock, go to TipRanks’ Stock Analysis page.